REFERENCES
- Fauci AS, Bartlett JB, Goosby EP, et al. The guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Accessed January 28, 2000. Available at www.hivatis.org
- Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA. 1998;280:78–86.
- Havlier DV, Tierney C, Friedland GH, et al. In vivo antago-nism with zidovudine plus stavudine combination therapy. J Infect Dis. 2000;182:321–325.
- Staszewski S, Loveday C, Picazo J, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA. 1996;276:111–117.
- Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 1995;333:1662–1669.
- Katlama C, Ingland D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: randomized controlled com-parison with zidovudine monotherapy. JAMA 1999;276:118–125.
- Foudraine NA, de Jong JJ, Waverling GJ, et al. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS. 1998;12: 1513–1519.
- Kuritzkes DR, Marschner I, Johnson VA, et al. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double blind, placebo-controlled trial. AIDS. 1999;13:685–694.
- Leibowitch J. The triple combination of stavudine, didanosine and lamivudine as first- or second-line treat-ment in individuals with advanced HIV infection. Antiviral Ther. 1997;2:125–128.
- Molina JM, Chene G, Ferchal F, et al. The ALBI: a random-ized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients in-fected with human immunodefiency virus. J Infect Dis. 1999;180:351–358.
- Eron JJ Jr, Murphy RL, Peterson D, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS. 2000;14:1601–1610.
- Wei LJ, Lin DY, Weissfeld L. Regression analysis of multi-variate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc. 1989;84,:1065–1073.
- Prentice RL, Williams BJ, Peterson A. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373–379.
- Becker SL, Raffanti SR, Hansen NI, et al. Zidovudine and stavudine sequencing in HIV treatment planning: finding from the CHORUS HIV cohort. JAIDS. 200126: 72–81.
- Cox DR. Regression models and life-tables (with discus-sion). J Royal Stat Soc (B). 197234: 187–220.
- Lin DY, Wei U. The robust inference for the Cox propor-tional hazards model. J Am Stat Assoc. 1989;84:1074–1078.
- Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Stat Med. 1994;13:2233–2247.
- SAS Institute Inc. SAS/IML Software: Usage and Refer-ence, Version 8. Cary, NC: SAS Institute Inc.; 1997.
- SAS Institute Inc. SAS/STAT Software: Changes and En-hancements Through Release 6.12. Cary, NC: SAS Insti-tute Inc.; 1997.